Fei Li Kuang1, Bryan F Curtin2, Hawwa Alao2, Brent Piligian3, Alexis Berry3, Nicole Holland-Thomas3, Astin Powers4, Martha Quezado4, Keith Lumbard5, Michael P Fay6, Amy D Klion3, Sheila Kumar2, Paneez Khoury3. 1. Laboratory of Parasitic Diseases, NIAID, Bethesda, Md; Division of Allergy and Immunology, Northwestern University Feinberg School of Medicine, Chicago, Ill. Electronic address: feili.kuang@northwestern.edu. 2. Digestive Diseases Branch, NIDDK, National Institutes of Health, Bethesda, Md. 3. Laboratory of Parasitic Diseases, NIAID, Bethesda, Md. 4. Laboratory of Pathology, NCI, National Institutes of Health, Bethesda, Md. 5. Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Bethesda, Md. 6. Biostatistical Research Branch, NIAID, National Institutes of Health, Bethesda, Md.
Abstract
BACKGROUND: Eosinophilic gastrointestinal diseases (EGIDs) are defined by marked eosinophilia in the gastrointestinal (GI) tract resulting in a wide variety of GI symptoms. When accompanied by blood hypereosinophilia (HE; absolute eosinophil count ≥1500/mm3), EGID can occur as an isolated GI disorder (hypereosinophilic syndrome [HES]/EGID overlap) or as part of a multisystem hypereosinophilic syndrome (Multisystem HES). OBJECTIVE: To describe the GI disease of patients categorized as those with HES/EGID overlap versus those with Multisystem HES. METHODS: Consecutively enrolled patients on a natural history protocol to study eosinophilia with biopsy-proven EGID involving the esophagus, stomach, small-bowel, and/or colon were evaluated for clinical, histopathologic, and endoscopic features by retrospective chart review. RESULTS: Among the 56 patients with EGID and HE, 34 were categorized as HES/EGID overlap and 22 as Multisystem HES. Demographics, GI symptoms, and associated comorbidities were similar between the 2 groups. Multisegment GI eosinophilia was present in 20 of 30 (67%) patients who underwent tissue sampling of all 4 GI segments. Tissue eosinophilia in all 4 GI segments was found in 5 of 30 (17%) patients. Dietary therapy was more common in patients with HES/EGID overlap (65% vs 23%, P = .0028). Patients with Multisystem HES were more likely to receive glucocorticoids (100% vs 79%, P = .0349) and nonglucocorticoid systemic therapies (77% vs 38%, P = .0061). One-third (8 of 22) of patients with Multisystem HES presented with isolated GI symptoms before developing extraintestinal manifestations at a median of 1 year (range, 0.25-15 years). CONCLUSION: There are striking clinical similarities between patients with Multisystem HES and those with HES/EGID overlap, despite differing treatment approaches. Moreover, Multisystem HES can present with isolated GI involvement. Larger prospective studies are needed to confirm these findings. Published by Elsevier Inc.
BACKGROUND:Eosinophilic gastrointestinal diseases (EGIDs) are defined by marked eosinophilia in the gastrointestinal (GI) tract resulting in a wide variety of GI symptoms. When accompanied by blood hypereosinophilia (HE; absolute eosinophil count ≥1500/mm3), EGID can occur as an isolated GI disorder (hypereosinophilic syndrome [HES]/EGID overlap) or as part of a multisystem hypereosinophilic syndrome (Multisystem HES). OBJECTIVE: To describe the GI disease of patients categorized as those with HES/EGID overlap versus those with Multisystem HES. METHODS: Consecutively enrolled patients on a natural history protocol to study eosinophilia with biopsy-proven EGID involving the esophagus, stomach, small-bowel, and/or colon were evaluated for clinical, histopathologic, and endoscopic features by retrospective chart review. RESULTS: Among the 56 patients with EGID and HE, 34 were categorized as HES/EGID overlap and 22 as Multisystem HES. Demographics, GI symptoms, and associated comorbidities were similar between the 2 groups. Multisegment GIeosinophilia was present in 20 of 30 (67%) patients who underwent tissue sampling of all 4 GI segments. Tissue eosinophilia in all 4 GI segments was found in 5 of 30 (17%) patients. Dietary therapy was more common in patients with HES/EGID overlap (65% vs 23%, P = .0028). Patients with Multisystem HES were more likely to receive glucocorticoids (100% vs 79%, P = .0349) and nonglucocorticoid systemic therapies (77% vs 38%, P = .0061). One-third (8 of 22) of patients with Multisystem HES presented with isolated GI symptoms before developing extraintestinal manifestations at a median of 1 year (range, 0.25-15 years). CONCLUSION: There are striking clinical similarities between patients with Multisystem HES and those with HES/EGID overlap, despite differing treatment approaches. Moreover, Multisystem HES can present with isolated GI involvement. Larger prospective studies are needed to confirm these findings. Published by Elsevier Inc.
Authors: Joseph Y Chang; Rok Seon Choung; Ru Min Lee; G Richard Locke; Cathy D Schleck; Alan R Zinsmeister; Thomas C Smyrk; Nicholas J Talley Journal: Clin Gastroenterol Hepatol Date: 2010-05-06 Impact factor: 11.382
Authors: Julie M Caldwell; Margaret H Collins; Emily M Stucke; Philip E Putnam; James P Franciosi; Jonathan P Kushner; J Pablo Abonia; Marc E Rothenberg Journal: J Allergy Clin Immunol Date: 2014-09-15 Impact factor: 10.793
Authors: Wolfgang B Gaertner; Jennifer E Macdonald; Mary R Kwaan; Christopher Shepela; Robert Madoff; Jose Jessurun; Genevieve B Melton Journal: Gastroenterol Res Pract Date: 2011-07-10 Impact factor: 2.260
Authors: Jong Sub Choi; Shin Jie Choi; Kyung Jae Lee; Ahlee Kim; Jung Kyung Yoo; Hye Ran Yang; Jin Soo Moon; Ju Young Chang; Jae Sung Ko; Gyeong Hoon Kang Journal: Pediatr Gastroenterol Hepatol Nutr Date: 2015-12-23
Authors: Aubri M Waters; Hyun J Park; Andrew L Weskamp; Allyson Mateja; Megan E Kachur; Jonathan J Lyons; Benjamin J Rosen; Nathan A Boggs Journal: J Allergy Clin Immunol Pract Date: 2022-01-12